Oncimmune Limited

Oncimmune Limited (Oncimmune) is engaged in providing a variety of innovative pharmaceutical products. The company is principally involved in commercialization of cancer related technologies. It offers patented EarlyCDT technology that is widely applicable in the detection of lung cancer. The company is also involved in the development of novel tests for various solid-tumor cancers including stomach, pancreas, breast, colon, and prostate. It operates in collaboration with Lachesis Seed Capital, Balderton Capital and the University of Nottingham. The company commercializes EarlyCDT-lung tests through its own panel of medical professionals in Canada and the US. Oncimmune is headquartered in Nottingham, the UK.

Street: 
Clinical Sciences Building
City: 
Nottingham
Postcode: 
NG5 1PB
Federal State : 
United Kingdom
WebSite: 
www.oncimmune.co.uk
Fax: 
44-115-8231958

Company Index Score

Current Index Score Historical Index Score
  • Oncimmune Limited currently scores 50 % in the index.
  • Oncimmune Limited is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Oncimmune Limited is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets